Last reviewed · How we verify
biphasic insulin aspart
Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage.
Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biphasic insulin aspart |
|---|---|
| Also known as | NovoLog, BIasp, NovoLog Mix 70/30, NovoMix 30, BIASP |
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin analog (biphasic) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Biphasic insulin aspart combines 30% rapid-acting insulin aspart and 70% insulin aspart protamine suspension, mimicking the body's natural biphasic insulin secretion pattern. The rapid-acting component provides quick postprandial glucose control, while the protamine-bound component offers intermediate basal coverage. This dual action reduces blood glucose levels by promoting cellular glucose uptake and suppressing hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes (PHASE4)
- Comparison of Two Biphasic Insulin Regimens (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biphasic insulin aspart CI brief — competitive landscape report
- biphasic insulin aspart updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI